Passive transfer of neutralizing antibodies against HIV-1 can prevent infection in macaques and seems to delay HIV-1 rebound in humans. Anti-HIV antibodies are therefore of great interest for vaccine design. However, the basis for their in vivo activity has been difficult to evaluate systematically because of a paucity of small animal models for HIV infection. Here we report a genetically humanized mouse model that incorporates a luciferase reporter for rapid quantitation of HIV entry. An antibody's ability to block viral entry in this in vivo model is a function of its bioavailability, direct neutralizing activity, and effector functions.
CITATION STYLE
Pietzsch, J., Gruell, H., Bournazos, S., Donovan, B. M., Klein, F., Diskin, R., … Nussenzweig, M. C. (2012). A mouse model for HIV-1 entry. Proceedings of the National Academy of Sciences of the United States of America, 109(39), 15859–15864. https://doi.org/10.1073/pnas.1213409109
Mendeley helps you to discover research relevant for your work.